{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:39:24Z","timestamp":1772793564567,"version":"3.50.1"},"reference-count":106,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2069,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1111\/j.1478-3231.2009.02145.x","type":"journal-article","created":{"date-parts":[[2009,10,19]],"date-time":"2009-10-19T08:03:07Z","timestamp":1255939387000},"page":"5-18","source":"Crossref","is-referenced-by-count":26,"title":["Current issues in the management of paediatric viral hepatitis"],"prefix":"10.1111","volume":"30","author":[{"given":"Latifa T. F.","family":"Yeung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB1","doi-asserted-by":"crossref","unstructured":"1.\u00e2\u0080\u0082 Salama II , Samy SM , Shaaban FA , Hassanin AI , Abou Ismail LA. Seroprevalence of hepatitis A among children of different socioeconomic status in Cairo. East Mediterr Health J 2007; 13: 1256\u00e2\u0080\u009364.","DOI":"10.26719\/2007.13.6.1256"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB2","doi-asserted-by":"crossref","unstructured":"2.\u00e2\u0080\u0082 Ciocca M , Moreira-Silva SF , Alegria S , et al. Hepatitis A as an etiologic agent of acute liver failure in Latin America. Pediatr Infect Dis J 2007; 26: 711\u00e2\u0080\u00935.","DOI":"10.1097\/INF.0b013e3180f60bed"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB3","unstructured":"3.\u00e2\u0080\u0082 Chen YC , Huang LT , Wang SM , Tiao MM , Liu JW. Acute hepatitis A infection in children: a 20-year experience of a medical center in Southern Taiwan. Acta Paediatr Taiwan 2007; 48: 131\u00e2\u0080\u00934."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB4","doi-asserted-by":"crossref","unstructured":"4.\u00e2\u0080\u0082 Ciocca M , Ramonet M , Cuarterolo M , et al. Prognostic factors in paediatric acute liver failure. Arch Dis Child 2008; 93: 48\u00e2\u0080\u009351.","DOI":"10.1136\/adc.2006.115113"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB5","doi-asserted-by":"crossref","unstructured":"5.\u00e2\u0080\u0082 Ellis A , Ruttimann RW , Jacobs RJ , Meyerhoff AS , Innis BL. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev Panam Salud Publica 2007; 21: 345\u00e2\u0080\u009356.","DOI":"10.1590\/S1020-49892007000500002"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB6","doi-asserted-by":"crossref","unstructured":"6.\u00e2\u0080\u0082 Lopez E , Debbag R , Coudeville L , Baron-Papillon F , Armoni J. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health\u00e2\u0080\u0093economic analysis. J Gastroenterol 2007; 42: 152\u00e2\u0080\u009360.","DOI":"10.1007\/s00535-006-1984-x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB7","doi-asserted-by":"crossref","unstructured":"7.\u00e2\u0080\u0082 Aydogdu S , Ozgenc F , Yurtsever S , et al. Our experience with fulminant hepatic failure in Turkish children: etiology and outcome. J Trop Pediatr 2003; 49: 367\u00e2\u0080\u009370.","DOI":"10.1093\/tropej\/49.6.367"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB8","unstructured":"8.\u00e2\u0080\u0082 Mathur P , Arora NK. Epidemiological transition of hepatitis A in India: issues for vaccination in developing countries. Indian J Med Res 2008; 128: 699\u00e2\u0080\u0093704."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB9","doi-asserted-by":"crossref","unstructured":"9.\u00e2\u0080\u0082 Arora NK , Nanda SK , Gulati S , et al. Acute viral hepatitis types E, A, and B singly and in combination in acute liver failure in children in north India. J Med Virol 1996; 48: 215\u00e2\u0080\u009321.","DOI":"10.1002\/(SICI)1096-9071(199603)48:3<215::AID-JMV1>3.0.CO;2-B"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB10","unstructured":"10.\u00e2\u0080\u0082 Samanta T , Ganguly S. Aetiology, clinical profile and prognostic indicators for children with acute liver failure admitted in a teaching hospital in Kolkata. Trop Gastroenterol 2007; 28: 135\u00e2\u0080\u00939."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB11","unstructured":"11.\u00e2\u0080\u0082 Bhowmick K , Mammen A , Moses PD , et al. Hepatitis A in pediatric acute liver failure in southern India. Indian J Gastroenterol 2005; 24: 34."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB12","unstructured":"12.\u00e2\u0080\u0082 Wasley A , Grytdal S , Gallagher K. Surveillance for acute viral hepatitis \u00e2\u0080\u0093 United States, 2006. MMWR Surveill Summ 2008; 57: 1\u00e2\u0080\u009324."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB13","unstructured":"13.\u00e2\u0080\u0082 Williams I, Wasley A , Darling N , Singleton J , Fischer G . Hepatitis A vaccination coverage among children aged 24\u00e2\u0080\u009335 months \u00e2\u0080\u0093 United States, 2004\u00e2\u0080\u00932005. Morb Mortal Wkly Rep 2007; 56: 678\u00e2\u0080\u009381."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB14","doi-asserted-by":"crossref","unstructured":"14.\u00e2\u0080\u0082American Academy of Pediatrics: Committee on Infectious Diseases. Hepatitis A vaccine recommendations. Pediatrics 2007; 120: 189\u00e2\u0080\u009399.","DOI":"10.1542\/peds.2007-1088"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB15","doi-asserted-by":"crossref","unstructured":"15.\u00e2\u0080\u0082 Blaine Hollinger F , Bell B , Levy-Bruhl D , et al. Hepatitis A and B vaccination and public health. J Viral Hepat 2007; 14 (Suppl. 1): 1\u00e2\u0080\u00935.","DOI":"10.1111\/j.1365-2893.2007.00924.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB16","doi-asserted-by":"crossref","unstructured":"16.\u00e2\u0080\u0082 Van Herck K , Leroux-Roels G , Van Damme P , Srinivasa K , Hoet B. Ten-year antibody persistence induced by hepatitis A and B vaccine (Twinrix) in adults. Travel Med Infect Dis 2007; 5: 171\u00e2\u0080\u00935.","DOI":"10.1016\/j.tmaid.2006.07.003"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB17","doi-asserted-by":"crossref","unstructured":"17.\u00e2\u0080\u0082 Diaz-Mitoma F , Law B , Subramanya A , Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 2008; 26: 1759\u00e2\u0080\u009363.","DOI":"10.1016\/j.vaccine.2008.01.014"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB18","doi-asserted-by":"crossref","unstructured":"18.\u00e2\u0080\u0082 Victor JC , Monto AS , Surdina TY , et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007; 357: 1685\u00e2\u0080\u009394.","DOI":"10.1056\/NEJMoa070546"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB19","doi-asserted-by":"crossref","unstructured":"19.\u00e2\u0080\u0082 Baker CJ. Another success for hepatitis A vaccine. N Engl J Med 2007; 357: 1757\u00e2\u0080\u00939.","DOI":"10.1056\/NEJMe078189"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB20","doi-asserted-by":"crossref","unstructured":"20.\u00e2\u0080\u0082 Bauch CT , Rao AS , Pham BZ , et al. A dynamic model for assessing universal hepatitis A vaccination in Canada. Vaccine 2007; 25: 1719\u00e2\u0080\u009326.","DOI":"10.1016\/j.vaccine.2006.11.020"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB21","doi-asserted-by":"crossref","unstructured":"21.\u00e2\u0080\u0082 Chang MH. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res 2009; 181: 85\u00e2\u0080\u009394.","DOI":"10.1007\/978-3-540-69297-3_10"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB22","doi-asserted-by":"crossref","unstructured":"22.\u00e2\u0080\u0082 Omenaca F , Garcia-Sicilia J , Boceta R , Sistiaga-Hernando A , Garcia-Corbeira P. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. Pediatr Infect Dis J 2007; 26: 824\u00e2\u0080\u00939.","DOI":"10.1097\/INF.0b013e318124a9c8"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB23","doi-asserted-by":"crossref","unstructured":"23.\u00e2\u0080\u0082 Stojanov S , Liese JG , Belohradsky BH , et al. Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP\u00e2\u0080\u0093IPV\u00e2\u0080\u0093PRP approximately T-HBs) combination vaccine. Vaccine 2007; 25: 7549\u00e2\u0080\u009358.","DOI":"10.1016\/j.vaccine.2007.08.028"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB24","doi-asserted-by":"crossref","unstructured":"24.\u00e2\u0080\u0082 Hammitt LL , Hennessy TW , Fiore AE , et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25: 6958\u00e2\u0080\u009364.","DOI":"10.1016\/j.vaccine.2007.06.059"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB25","doi-asserted-by":"crossref","unstructured":"25.\u00e2\u0080\u0082 Su FH , Cheng SH , Li CY , et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 8085\u00e2\u0080\u009390.","DOI":"10.1016\/j.vaccine.2007.09.013"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB26","doi-asserted-by":"crossref","unstructured":"26.\u00e2\u0080\u0082 Pielak KL , McIntyre CC , Remple VP , Buxton JA , Skowronski DM. One arm or two? Concurrent administration of meningococcal C conjugate and hepatitis B vaccines in pre-teens. Can J Public Health 2008; 99: 52\u00e2\u0080\u00936.","DOI":"10.1007\/BF03403741"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB27","doi-asserted-by":"crossref","unstructured":"27.\u00e2\u0080\u0082 Mikaeloff Y , Caridade G , Rossier M , Suissa S , Tardieu M. Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 2007; 161: 1176\u00e2\u0080\u009382.","DOI":"10.1001\/archpedi.161.12.1176"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB28","doi-asserted-by":"crossref","unstructured":"28.\u00e2\u0080\u0082 Velu V , Saravanan S , Nandakumar S , et al. Transmission of \u00e2\u0080\u009ca\u00e2\u0080\u009d determinant variants of hepatitis B virus in immunized babies born to HBsAg carrier mothers. Jpn J Infect Dis 2008; 61: 73\u00e2\u0080\u00936.","DOI":"10.7883\/yoken.JJID.2008.73"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB29","doi-asserted-by":"crossref","unstructured":"29.\u00e2\u0080\u0082 Ijaz S , Khulan J , Bissett SL , et al. A low rate of hepatitis B virus vaccine breakthrough infections in Mongolia. J Med Virol 2006; 78: 1554\u00e2\u0080\u00939.","DOI":"10.1002\/jmv.20738"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB30","doi-asserted-by":"crossref","unstructured":"30.\u00e2\u0080\u0082 Mu SC , Lin YM , Jow GM , Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol 2009; 50: 264\u00e2\u0080\u009372.","DOI":"10.1016\/j.jhep.2008.09.017"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB31","doi-asserted-by":"crossref","unstructured":"31.\u00e2\u0080\u0082 Sheldon J , Ramos B , Garcia-Samaniego J , et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV\/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007; 46: 279\u00e2\u0080\u009382.","DOI":"10.1097\/QAI.0b013e318154bd89"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB32","doi-asserted-by":"crossref","unstructured":"32.\u00e2\u0080\u0082 Liu CJ , Kao JH , Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005; 25: 1097\u00e2\u0080\u0093107.","DOI":"10.1111\/j.1478-3231.2005.01177.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB33","doi-asserted-by":"crossref","unstructured":"33.\u00e2\u0080\u0082 Wu TC , Tong MJ , Hwang B , Lee SD , Hu MM. Primary hepatocellular carcinoma and hepatitis B infection during childhood. Hepatology 1987; 7: 46\u00e2\u0080\u00938.","DOI":"10.1002\/hep.1840070111"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB34","doi-asserted-by":"crossref","unstructured":"34.\u00e2\u0080\u0082 Fujisawa T , Komatsu H , Inui A , et al. Long-term outcome of chronic hepatitis B in adolescents or young adults in follow-up from childhood. J Pediatr Gastroenterol Nutr 2000; 30: 201\u00e2\u0080\u00936.","DOI":"10.1097\/00005176-200002000-00019"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB35","doi-asserted-by":"crossref","unstructured":"35.\u00e2\u0080\u0082 Bortolotti F , Guido M , Bartolacci S , et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006; 43: 556\u00e2\u0080\u009362.","DOI":"10.1002\/hep.21077"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB36","doi-asserted-by":"crossref","unstructured":"36.\u00e2\u0080\u0082 Sagnelli E , Stroffolini T , Mele A , Imparato M , Almasio PL. Chronic hepatitis B in Italy: new features of an old disease \u00e2\u0080\u0093 approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection. Clin Infect Dis 2008; 46: 110\u00e2\u0080\u00933.","DOI":"10.1086\/524074"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB37","doi-asserted-by":"crossref","unstructured":"37.\u00e2\u0080\u0082 Fattovich G , Olivari N , Pasino M , et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008; 57: 84\u00e2\u0080\u009390.","DOI":"10.1136\/gut.2007.128496"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB38","doi-asserted-by":"crossref","unstructured":"38.\u00e2\u0080\u0082 Lok AS , McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507\u00e2\u0080\u009339.","DOI":"10.1002\/hep.21513"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB39","doi-asserted-by":"crossref","unstructured":"39.\u00e2\u0080\u0082 Chen CJ , Yang HI , Su J , et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65\u00e2\u0080\u009373.","DOI":"10.1001\/jama.295.1.65"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB40","doi-asserted-by":"crossref","unstructured":"40.\u00e2\u0080\u0082 Iloeje UH , Yang HI , Su J , et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678\u00e2\u0080\u009386.","DOI":"10.1053\/j.gastro.2005.11.016"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB41","doi-asserted-by":"crossref","unstructured":"41.\u00e2\u0080\u0082 Mendy ME , McConkey SJ , Sande van der MA , et al. Changes in viral load and HBsAg and HBeAg status with age in HBV chronic carriers in the Gambia. J Virol 2008; 5: 49.","DOI":"10.1186\/1743-422X-5-49"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB42","doi-asserted-by":"crossref","unstructured":"42.\u00e2\u0080\u0082 Lai CL , Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat 2007; 14 (Suppl. 1): 6\u00e2\u0080\u009310.","DOI":"10.1111\/j.1365-2893.2007.00909.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB43","unstructured":"43.\u00e2\u0080\u0082 Lin ZQ , Fang F , Guo ZF , Chen Q. Effect of interferon-alpha treatment in children with hepatitis B e antigen-positive chronic hepatitis B virus infection: a meta-analysis of follow-up for six months to two years. Zhonghua Er Ke Za Zhi 2007; 45: 592\u00e2\u0080\u00938."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB44","doi-asserted-by":"crossref","unstructured":"44.\u00e2\u0080\u0082 Jonas MM , Mizerski J , Badia IB , et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706\u00e2\u0080\u009313.","DOI":"10.1056\/NEJMoa012452"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB45","doi-asserted-by":"crossref","unstructured":"45.\u00e2\u0080\u0082 Jonas MM , Kelly D , Pollack H , et al. Safety, efficacy, and pharmacokinetics of adefovir diprivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008; 47: 1863\u00e2\u0080\u009371.","DOI":"10.1002\/hep.22250"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB46","doi-asserted-by":"crossref","unstructured":"46.\u00e2\u0080\u0082 Jonas MM , Little NR , Gardner SD. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J Viral Hep 2008; 15: 20\u00e2\u0080\u00937.","DOI":"10.1111\/j.1365-2893.2007.00891.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB47","unstructured":"47.\u00e2\u0080\u0082 Lai CL , Lin HJ , Lau JN , et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991; 78: 155\u00e2\u0080\u009363."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB48","doi-asserted-by":"crossref","unstructured":"48.\u00e2\u0080\u0082 Gregorio GV , Jara P , Hierro L , et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23: 700\u00e2\u0080\u00937.","DOI":"10.1053\/jhep.1996.v23.pm0008666320"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB49","doi-asserted-by":"crossref","unstructured":"49.\u00e2\u0080\u0082 Boxall EH , Sira J , Ballard AL , Davies P , Kelly DA. Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol 2006; 78: 888\u00e2\u0080\u009395.","DOI":"10.1002\/jmv.20637"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB50","doi-asserted-by":"crossref","unstructured":"50.\u00e2\u0080\u0082 Chan HL , Heathcote EJ , Marcellin P , et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745\u00e2\u0080\u009354.","DOI":"10.7326\/0003-4819-147-11-200712040-00183"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB51","doi-asserted-by":"crossref","unstructured":"51.\u00e2\u0080\u0082 Hou J , Yin YK , Xu D , et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 447\u00e2\u0080\u009354.","DOI":"10.1002\/hep.22075"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB52","doi-asserted-by":"crossref","unstructured":"52.\u00e2\u0080\u0082 Lai CL , Gane E , Liaw YF , et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576\u00e2\u0080\u009388.","DOI":"10.1056\/NEJMoa066422"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB53","doi-asserted-by":"crossref","unstructured":"53.\u00e2\u0080\u0082 Marcellin P , Heathcote EJ , Buti M , et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442\u00e2\u0080\u009355.","DOI":"10.1056\/NEJMoa0802878"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB54","doi-asserted-by":"crossref","unstructured":"54.\u00e2\u0080\u0082 Lai CL , Yuen MF. Chronic hepatitis B \u00e2\u0080\u0093 new goals, new treatment. N Engl J Med 2008; 359: 2488\u00e2\u0080\u009391.","DOI":"10.1056\/NEJMe0808185"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB55","doi-asserted-by":"crossref","unstructured":"55.\u00e2\u0080\u0082 Bortolotti F , Jara P , Barbera C , et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715\u00e2\u0080\u00938.","DOI":"10.1136\/gut.46.5.715"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB56","doi-asserted-by":"crossref","unstructured":"56.\u00e2\u0080\u0082 Marx G , Martin SR , Chicoine JF , Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002; 186: 295\u00e2\u0080\u0093301.","DOI":"10.1086\/341508"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB57","doi-asserted-by":"crossref","unstructured":"57.\u00e2\u0080\u0082 Hsu HY , Tsai HY , Wu TC , et al. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int 2008; 28: 1288\u00e2\u0080\u009397.","DOI":"10.1111\/j.1478-3231.2008.01746.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB58","doi-asserted-by":"crossref","unstructured":"58.\u00e2\u0080\u0082 Yuen MF , Hui CK , Cheng CC , et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139\u00e2\u0080\u009345.","DOI":"10.1053\/jhep.2001.25273"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB59","doi-asserted-by":"crossref","unstructured":"59.\u00e2\u0080\u0082International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535\u00e2\u0080\u00939.","DOI":"10.1016\/S0140-6736(98)07236-5"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB60","doi-asserted-by":"crossref","unstructured":"60.\u00e2\u0080\u0082 Camma C , Giunta M , Andreone P , Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34: 593\u00e2\u0080\u0093602.","DOI":"10.1016\/S0168-8278(01)00005-8"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB61","doi-asserted-by":"crossref","unstructured":"61.\u00e2\u0080\u0082 Torre D , Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996; 23: 131\u00e2\u0080\u00937.","DOI":"10.1093\/clinids\/23.1.131"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB62","unstructured":"62.\u00e2\u0080\u0082 Vajro P , Migliaro F , Fontanella A , Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998; 61: 219\u00e2\u0080\u009323."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB63","doi-asserted-by":"crossref","unstructured":"63.\u00e2\u0080\u0082 Narkewicz MR , Smith D , Silverman A , Vierling J , Sokol RJ. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr 1995; 127: 815\u00e2\u0080\u00938.","DOI":"10.1016\/S0022-3476(95)70181-8"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB64","doi-asserted-by":"crossref","unstructured":"64.\u00e2\u0080\u0082 Burczynska B , Madalinski K , Pawlowska J , et al. The value of quantitative measurement of HBeAg and HBsAg before interferon-alpha treatment of chronic hepatitis B in children. J Hepatol 1994; 21: 1097\u00e2\u0080\u0093102.","DOI":"10.1016\/S0168-8278(05)80624-5"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB65","doi-asserted-by":"crossref","unstructured":"65.\u00e2\u0080\u0082 D'Antiga L , Aw M , Atkins M , et al. Combined lamivudine\/interferon-alpha treatment in \u00e2\u0080\u009cimmunotolerant\u00e2\u0080\u009d children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006; 148: 228\u00e2\u0080\u0093233.","DOI":"10.1016\/j.jpeds.2005.09.020"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB66","doi-asserted-by":"crossref","unstructured":"66.\u00e2\u0080\u0082 Andreani T , Serfaty L , Mohand D , et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007; 5: 636\u00e2\u0080\u009341.","DOI":"10.1016\/j.cgh.2007.01.005"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB67","doi-asserted-by":"crossref","unstructured":"67.\u00e2\u0080\u0082 Iorio R , Giannattasio A , Cirillo F , D'Alessandro L , Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007; 45: 943\u00e2\u0080\u00939.","DOI":"10.1086\/521864"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB68","doi-asserted-by":"crossref","unstructured":"68.\u00e2\u0080\u0082 Zacharakis G , Koskinas J , Kotsiou S , et al. Natural history of chronic hepatitis B virus infection in children of different ethnic origins: a cohort study with up to 12 years' follow-up in northern Greece. J Pediatr Gastroenterol Nutr 2007; 44: 84\u00e2\u0080\u009391.","DOI":"10.1097\/01.mpg.0000243438.47334.07"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB69","doi-asserted-by":"crossref","unstructured":"69.\u00e2\u0080\u0082 Soderstrom A , Lindh M , Ekholm K , et al. Predictive factors and virological response to interferon treatment in children with chronic hepatitis B. Scand J Infect Dis 2005; 37: 40\u00e2\u0080\u00937.","DOI":"10.1080\/00365540410026031"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB70","unstructured":"70.\u00e2\u0080\u0082 Ozen H , Kocak N , Gurakan F , Yuce A. Recombinant interferon-alpha-2A with or without steroid pretreatment in children with chronic hepatitis B. Turk J Pediatr 1998; 40: 503\u00e2\u0080\u009314."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB71","doi-asserted-by":"crossref","unstructured":"71.\u00e2\u0080\u0082 Kim HS , Kim JW , Chung KS. Treatment of chronic hepatitis B in children with prednisolone withdrawal followed by recombinant interferon alpha. Yonsei Med J 1998; 39: 309\u00e2\u0080\u009316.","DOI":"10.3349\/ymj.1998.39.4.309"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB72","doi-asserted-by":"crossref","unstructured":"72.\u00e2\u0080\u0082 Vajro P , Tedesco M , Fontanella A , et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996; 15: 223\u00e2\u0080\u009331.","DOI":"10.1097\/00006454-199603000-00010"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB73","unstructured":"73.\u00e2\u0080\u0082 Gomez Camacho F , Poyato Gonzalez A , Vignote Alguacil ML , et al. Comparison of 2 treatment strategies with prednisone and interferon in chronic hepatitis B. Rev Esp Enferm Dig 1996; 88: 185\u00e2\u0080\u009390."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB74","doi-asserted-by":"crossref","unstructured":"74.\u00e2\u0080\u0082 Giacchino R , Main J , Timitilli A , et al. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995; 15: 143\u00e2\u0080\u00938.","DOI":"10.1111\/j.1600-0676.1995.tb00661.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB75","doi-asserted-by":"crossref","unstructured":"75.\u00e2\u0080\u0082 Utili R , Sagnelli E , Gaeta GB , et al. Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study. J Hepatol 1994; 20: 163\u00e2\u0080\u00937.","DOI":"10.1016\/S0168-8278(05)80053-4"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB76","doi-asserted-by":"crossref","unstructured":"76.\u00e2\u0080\u0082 Mellerup MT , Krogsgaard K , Mathurin P , Gluud C , Poynard T. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database Syst Rev 2002:CD000345.","DOI":"10.1002\/14651858.CD000345"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB77","doi-asserted-by":"crossref","unstructured":"77.\u00e2\u0080\u0082 Barlow CF , Priebe CJ , Mulliken JB , et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998; 132: 527\u00e2\u0080\u009330.","DOI":"10.1016\/S0022-3476(98)70034-4"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB78","doi-asserted-by":"crossref","unstructured":"78.\u00e2\u0080\u0082 Dubois J , Hershon L , Carmant L , et al. Toxicity profile of interferon alfa-2b in children: a prospective evaluation. J Pediatr 1999; 135: 782\u00e2\u0080\u00935.","DOI":"10.1016\/S0022-3476(99)70104-6"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB79","doi-asserted-by":"crossref","unstructured":"79.\u00e2\u0080\u0082 Chu CM , Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepatol 2007; 14: 147\u00e2\u0080\u009352.","DOI":"10.1111\/j.1365-2893.2006.00810.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB80","doi-asserted-by":"crossref","unstructured":"80.\u00e2\u0080\u0082 Yeung L , King S , Roberts E. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223\u00e2\u0080\u00939.","DOI":"10.1053\/jhep.2001.25885"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB81","doi-asserted-by":"crossref","unstructured":"81.\u00e2\u0080\u0082Canadian Association for the Study of the Liver Consensus Conference Rapporteur Group. Canadian Consensus Conference on the Management of Viral Hepatitis. Can J Gastroenterol 2000; 14: 5B\u00e2\u0080\u009320B.","DOI":"10.1155\/2000\/309605"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB82","doi-asserted-by":"crossref","unstructured":"82.\u00e2\u0080\u0082American Academy of Pediatrics: Committee on Infectious Diseases. Hepatitis C virus infection. Pediatrics 1998; 101: 481\u00e2\u0080\u00935.","DOI":"10.1542\/peds.101.3.481"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB83","unstructured":"83.\u00e2\u0080\u0082 Veronesi L , Verrotti Di Pianella C , Benassi L , et al. Mother to child transmission of hepatitis C virus in a province of northern Italy. J Prev Med Hyg 2007; 48: 47\u00e2\u0080\u00939."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB84","doi-asserted-by":"crossref","unstructured":"84.\u00e2\u0080\u0082 Marine-Barjoan E , Berrebi A , Giordanengo V , et al. HCV\/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS 2007; 21: 1811\u00e2\u0080\u00935.","DOI":"10.1097\/QAD.0b013e3282703810"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB85","doi-asserted-by":"crossref","unstructured":"85.\u00e2\u0080\u0082 England K , Pembrey L , Tovo PA , Newell ML. Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers. Acta Paediatr 2005; 94: 444\u00e2\u0080\u009350.","DOI":"10.1111\/j.1651-2227.2005.tb01916.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB86","doi-asserted-by":"crossref","unstructured":"86.\u00e2\u0080\u0082 Polywka S , Pembrey L , Tovo PA , Newell ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006; 78: 305\u00e2\u0080\u009310.","DOI":"10.1002\/jmv.20540"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB87","doi-asserted-by":"crossref","unstructured":"87.\u00e2\u0080\u0082 Yeung LT , To T , King SM , Roberts EA. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepatol 2007; 14: 797\u00e2\u0080\u0093805.","DOI":"10.1111\/j.1365-2893.2007.00873.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB88","doi-asserted-by":"crossref","unstructured":"88.\u00e2\u0080\u0082 Simanis R , Lejniece S , Sochnevs A , et al. Natural clearance of hepatitis C virus in hemophilia patients. Medicina 2008; 44: 15\u00e2\u0080\u009321.","DOI":"10.3390\/medicina44010003"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB89","doi-asserted-by":"crossref","unstructured":"89.\u00e2\u0080\u0082 El-Hawary MA , El-Raziky MS , Esmat G , et al. Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol 2007; 13: 2846\u00e2\u0080\u009351.","DOI":"10.3748\/wjg.v13.i20.2846"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB90","doi-asserted-by":"crossref","unstructured":"90.\u00e2\u0080\u0082 Goodman ZD , Makhlouf HR , Liu L , et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47: 836\u00e2\u0080\u009343.","DOI":"10.1002\/hep.22094"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB91","doi-asserted-by":"crossref","unstructured":"91.\u00e2\u0080\u0082 Bortolotti F , Verucchi G , Camma C , et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900\u00e2\u0080\u00937.","DOI":"10.1053\/j.gastro.2008.02.082"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB92","doi-asserted-by":"crossref","unstructured":"92.\u00e2\u0080\u0082 Kao JT , Wang JH , Hung CH , et al. Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C-endemic area: cross-sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. Liver Int 2008; 28: 1298\u00e2\u0080\u0093304.","DOI":"10.1111\/j.1478-3231.2008.01844.x"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB93","unstructured":"93.\u00e2\u0080\u0082 Liakina V , Speiciene D , Irnius A , Semuchiniene T , Valantinas J. Association of the prevalence and grade of steatosis in patients with chronic hepatitis C with the host and viral factors. Acta Gastroenterol 2007; 70: 260\u00e2\u0080\u00936."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB94","doi-asserted-by":"crossref","unstructured":"94.\u00e2\u0080\u0082 Cua IH , Hui JM , Kench JG , George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 723\u00e2\u0080\u009331.","DOI":"10.1002\/hep.22392"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB95","doi-asserted-by":"crossref","unstructured":"95.\u00e2\u0080\u0082 Harris HE , Mieli-Vergani G , Kelly D , et al. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr 2007; 45: 335\u00e2\u0080\u009341.","DOI":"10.1097\/MPG.0b013e3180dc9337"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB96","doi-asserted-by":"crossref","unstructured":"96.\u00e2\u0080\u0082 Jara P , Hierro L , de la Vega A , et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008; 27: 142\u00e2\u0080\u00938.","DOI":"10.1097\/INF.0b013e318159836c"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB97","doi-asserted-by":"crossref","unstructured":"97.\u00e2\u0080\u0082 Kowala-Piaskowska A , Mozer-Lisewska I , Figlerowicz M , Sluzewski W. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiol Drug Saf 2007; 16: 1095\u00e2\u0080\u0093103.","DOI":"10.1002\/pds.1458"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB98","unstructured":"98.\u00e2\u0080\u0082 Schwarz KB , Gonzalez-Peralta PR , Murray KF , et al. PEG-interferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the PEDS-C trial. Hepatology 2008; 48: 418A."},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB99","doi-asserted-by":"crossref","unstructured":"99.\u00e2\u0080\u0082 Murray KF , Rodrigue JR , Gonzalez-Peralta RP , et al. Design of the PEDS-C trial: pegylated interferon+\/\u00e2\u0088\u0092 ribavirin for children with chronic hepatitis C viral infection. Clin Trials 2007; 4: 661\u00e2\u0080\u009373.","DOI":"10.1177\/1740774507085445"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB100","doi-asserted-by":"crossref","unstructured":"100.\u00e2\u0080\u0082 Forestier N , Reesink HW , Weegink CJ , et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007; 46: 640\u00e2\u0080\u00938.","DOI":"10.1002\/hep.21774"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB101","doi-asserted-by":"crossref","unstructured":"101.\u00e2\u0080\u0082 Maylin S , Martinot-Peignoux M , Moucari R , et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821\u00e2\u0080\u00939.","DOI":"10.1053\/j.gastro.2008.05.044"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB102","doi-asserted-by":"crossref","unstructured":"102.\u00e2\u0080\u0082 Lin A , Thadareddy A , Goldstein MJ , Lake-Bakaar G. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 2008; 80: 1720\u00e2\u0080\u00932.","DOI":"10.1002\/jmv.21257"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB103","doi-asserted-by":"crossref","unstructured":"103.\u00e2\u0080\u0082 Shrestha MP , Scott RM , Joshi DM , et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356: 895\u00e2\u0080\u0093903.","DOI":"10.1056\/NEJMoa061847"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB104","doi-asserted-by":"crossref","unstructured":"104.\u00e2\u0080\u0082 Zhang J , Liu CB , Li RC , et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 2009; 27: 1869\u00e2\u0080\u009374.","DOI":"10.1016\/j.vaccine.2008.12.061"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB105","doi-asserted-by":"crossref","unstructured":"105.\u00e2\u0080\u0082 Tacke F , Trautwein C. Efficient recombinant hepatitis E virus vaccine: mission accomplished? Hepatology 2007; 46: 941\u00e2\u0080\u00933.","DOI":"10.1002\/hep.21909"},{"key":"10.1111\/j.1478-3231.2009.02145.x-BIB106","doi-asserted-by":"crossref","unstructured":"106.\u00e2\u0080\u0082 Krawczynski K. Hepatitis E vaccine \u00e2\u0080\u0093 ready for prime time? N Engl J Med 2007; 356: 949\u00e2\u0080\u009351.","DOI":"10.1056\/NEJMe068311"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2009.02145.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1478-3231.2009.02145.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T05:43:53Z","timestamp":1710654233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2009.02145.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2009.02145.x","relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}